Wealthfront Advisers LLC raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 187.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,464 shares of the life sciences company's stock after buying an additional 22,455 shares during the period. Wealthfront Advisers LLC's holdings in Illumina were worth $4,605,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in ILMN. WCM Investment Management LLC grew its position in Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock worth $354,933,000 after purchasing an additional 48,018 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock valued at $328,158,000 after buying an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after buying an additional 625,245 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
Illumina Trading Up 0.1 %
Illumina stock traded up $0.08 during mid-day trading on Monday, hitting $85.68. 1,344,174 shares of the company's stock were exchanged, compared to its average volume of 2,094,303. The company's 50 day simple moving average is $113.52 and its 200-day simple moving average is $129.86. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $13.57 billion, a P/E ratio of -11.16, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of research analyst reports. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Barclays reissued an "underweight" rating on shares of Illumina in a research note on Tuesday, March 11th. Guggenheim dropped their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Illumina has an average rating of "Moderate Buy" and an average target price of $140.90.
Read Our Latest Stock Analysis on Illumina
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
